These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 34511901)

  • 1. Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles.
    Piperno A; Sciortino MT; Giusto E; Montesi M; Panseri S; Scala A
    Int J Nanomedicine; 2021; 16():5981-6002. PubMed ID: 34511901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabrication and characterization of PLGA nanoparticles encapsulating large CRISPR-Cas9 plasmid.
    Jo A; Ringel-Scaia VM; McDaniel DK; Thomas CA; Zhang R; Riffle JS; Allen IC; Davis RM
    J Nanobiotechnology; 2020 Jan; 18(1):16. PubMed ID: 31959180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyester based nanovehicles for siRNA delivery.
    Xu Z; Wang D; Cheng Y; Yang M; Wu LP
    Mater Sci Eng C Mater Biol Appl; 2018 Nov; 92():1006-1015. PubMed ID: 30184724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
    Li C; Brant E; Budak H; Zhang B
    J Zhejiang Univ Sci B; 2021 Apr; 22(4):253-284. PubMed ID: 33835761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 one year later: a retrospect of CRISPR-Cas system in combating COVID-19.
    Zhan Y; Li XP; Yin JY
    Int J Biol Sci; 2021; 17(8):2080-2088. PubMed ID: 34131407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
    Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in stimuli-responsive polymeric carriers for controllable CRISPR/Cas9 gene editing system delivery.
    Ma P; Wang Q; Luo X; Mao L; Wang Z; Ye E; Loh XJ; Li Z; Wu YL
    Biomater Sci; 2023 Jul; 11(15):5078-5094. PubMed ID: 37282836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyester-based nanoparticles for nucleic acid delivery.
    Zhao J; Weng G; Li J; Zhu J; Zhao J
    Mater Sci Eng C Mater Biol Appl; 2018 Nov; 92():983-994. PubMed ID: 30184828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.
    Ma T; Chen X; Wang M
    Chembiochem; 2023 May; 24(9):e202200801. PubMed ID: 36780174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleic Acid-Based Technologies Targeting Coronaviruses.
    Le TK; Paris C; Khan KS; Robson F; Ng WL; Rocchi P
    Trends Biochem Sci; 2021 May; 46(5):351-365. PubMed ID: 33309323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLGA-Nanoparticles for Intracellular Delivery of the CRISPR-Complex to Elevate Fetal Globin Expression in Erythroid Cells.
    Cruz LJ; van Dijk T; Vepris O; Li TMWY; Schomann T; Baldazzi F; Kurita R; Nakamura Y; Grosveld F; Philipsen S; Eich C
    Biomaterials; 2021 Jan; 268():120580. PubMed ID: 33321292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems.
    Hejabi F; Abbaszadeh MS; Taji S; O'Neill A; Farjadian F; Doroudian M
    Front Chem; 2022; 10():957572. PubMed ID: 36092658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of CRISPR/Cas9 Plasmid DNA by Hyperbranched Polymeric Nanoparticles Enables Efficient Gene Editing.
    Xiu K; Saunders L; Wen L; Ruan J; Dong R; Song J; Yang D; Zhang J; Xu J; Chen YE; Ma PX
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
    Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
    Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic nanoparticles for the delivery of CRISPR/Cas9 gene editing system: classification and biomedical applications.
    Zheng Q; Wang W; Zhou Y; Mo J; Chang X; Zha Z; Zha L
    Biomater Sci; 2023 Aug; 11(16):5361-5389. PubMed ID: 37381725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active Delivery of CRISPR System Using Targetable or Controllable Nanocarriers.
    Lyu Y; Yang C; Lyu X; Pu K
    Small; 2021 Jun; 17(24):e2005222. PubMed ID: 33759340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for neurological disorders: challenges and recent advancements.
    Pena SA; Iyengar R; Eshraghi RS; Bencie N; Mittal J; Aljohani A; Mittal R; Eshraghi AA
    J Drug Target; 2020 Feb; 28(2):111-128. PubMed ID: 31195838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.